Targeted drug delivery strategies to treat lung metastasis

Expert Opinion on Drug Delivery

Volumn 6, Issue 10, 2009, Pages 1003-1016

  Bar, Jair ^a   Herbst, Roy S ^b   Onn, Amir ^b,c  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Aerosol; Antibody conjugated; Enhanced permeability and retention; Ligand targeted therapy; Liposomes; Magnetic targeting; Nanoparticle; Polymer conjugates; Vascular targeting agents

Indexed keywords

CAMPTOTHECIN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; D 99; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IMMUNOLIPOSOME; IODINATED POPPYSEED OIL; LIPOSOME; LURTOTECAN; MELPHALAN; MITOMYCIN C; MITOPODOZIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 IN 111; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYGLACTIN; POLYGLUTAMIC ACID; POLYLACTIC ACID; POLYMER; SMALL INTERFERING RNA; STRONTIUM 89; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; AEROSOL; BLADDER DISEASE; BONE MARROW TOXICITY; BONE PAIN; BREAST CANCER; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEASIBILITY STUDY; HEMATOLOGIC MALIGNANCY; HUMAN; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; LIVER TOXICITY; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAGNETISM; NEUROTOXICITY; NONHUMAN; PHARYNGITIS; POLYMER ENZYME LIPOSOME THERAPY; POLYMER ENZYME POLYMER PRODRUG THERAPY; RADIOFREQUENCY ABLATION; REVIEW; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY; TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

AEROSOLS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS;

EID: 70349389652     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903167926     Document Type: Review

References (90)

1. Crow J, Slavin G, Kreel L. Pulmonary metastasis: a pathologic and radiologic study. Cancer 1981;47(11):2595-2602 (Pubitemid 11113723)
2. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1(2):126-134
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2(8):706-714 (Pubitemid 47357522)
4. The International Registry of Lung Metastases, Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113(1):37-49
5. Quiros RM, Scott WJ. Surgical treatment of metastatic disease to the lung. Semin Oncol 2008;35(2):134-146
6. Alexander J, Haight C, Eschapasse H. Surgery in secondary cancer of the lung; results; indications. Bull Assoc Fr Etud Cancer 1951;38(1):96-104
7. Weksler B, Ng B, Lenert JT, et al. Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. Ann Thorac Surg 1993;56(2):209-214 (Pubitemid 23245125)
8. Hendriks JM, Grootenboers MJ, Schramel FM, et al. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 2004;78(6):1919-26; discussion 26-27
9. Grootenboers MJ, Hendriks JM, van Boven WJ, et al. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial. J Surg Oncol 2007;96(7):583-589
10. Schneider P, Foitzik T, Pohlen U, et al. Temporary unilateral microembolization of the lung-a new approach to regional chemotherapy for pulmonary metastases. J Surg Res 2002;107(2):159-166 (Pubitemid 35379655)
11. Schneider P, Kampfer S, Loddenkemper C, et al. Chemoembolization of the lung improves tumor control in a rat model. Clin Cancer Res 2002;8(7):2463-2468 (Pubitemid 34753624)
12. Vogl TJ, Wetter A, Lindemayr S, et al. Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience. Radiology 2005;234(3):917-922 (Pubitemid 40250838)
13. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004;1(4):315-320
14. Giovanella CB, Vernon KJ, Waldrep JC, et al.; inventor Research Development Foundation., assignee. Small particle liposome aerosols for delivery of anti-cancer drugs. US 7341739 B2; 2008
15. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004;10(7):2319-2326 (Pubitemid 38445689)
16. Otterson GA, Villalona-Calero MA, Sharma S, et al. PhaseI study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 2007;13(4):1246-1252
17. Koshkina NV, Agoulnik IY, Melton SL, et al. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 2003;8(2):249-254
18. Jia SF, Worth LL, Densmore CL, et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 2003;9(9):3462-3468
19. Densmore CL, Kleinerman ES, Gautam A, et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 2001;8(9):619-627 (Pubitemid 32912235)
20. Bhattarai SR, Kim SY, Jang KY, et al. Amphiphilic triblock copolymer poly(p-dioxanone-co-L-lactide)-block-poly(ethylene glycol), enhancement of gene expression and inhibition of lung metastasis by aerosol delivery. Gene Ther 2007;14(6):476-483
21. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007;2(8):495-499 (Pubitemid 47220067)
22. Plank C, Anton M, Rudolph C, et al. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther 2003;3(5):745-758 (Pubitemid 36934974)
23. Lubbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14patients with advanced solid tumors. Cancer Res 1996;56(20):4686-4693 (Pubitemid 26338071)
24. Wilson MW, Kerlan RK Jr, Fidelman NA, et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite - initial experience with four patients. Radiology 2004;230(1):287-293
25. Freshnews.com. FeRx Closes PhaseII/III Clinical Trial for Treatment of Primary Liver Cancer. 2004
26. Fortin-Ripoche JP, Martina MS, Gazeau F, et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology 2006;239(2):415-424
27. Riviere C, Martina MS, Tomita Y, et al. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. Radiology 2007;244(2):439-448 (Pubitemid 47080875)
28. trials.gov C. Studies conducted by ferx. 2005
29. Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11(17-18):812- 818 (Pubitemid 44280021)
30. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-6392 (Pubitemid 17221789)
31. Jisoptn HM, Kabanov AV. Polymer drugs in the clinical stage: advantages and prospects: Springer, Berlin; 2003
32. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-1181 (Pubitemid 35177372)
33. Hayes ME, Drummond DC, Kirpotin DB, et al. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther 2006;13(7):646-651
34. Sapra P, Moase EH, Ma J, et al. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004;10(3):1100-1111
35. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62(24):7190-7194 (Pubitemid 36025236)
36. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39(1-2):181-194
37. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16(9):1627-1636
38. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24(10):1210-1214 (Pubitemid 27477612)
39. Gradishar WJ, Tjulandin S, Davidson N, et al. PhaseIII trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-7803 (Pubitemid 46657376)
40. Maeda HAk, Kataoka K, Okano T. Proceedings of the International Symposium on Polymer Therapeutics-Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan. Polymer Drugs in the Clinical Stage: advantages and prospects: Springer, Berlin; 2003
41. Shaffer SA, Baker-Lee C, Kennedy J, et al. Invitro and invivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol 2007;59(4):537-548
42. Albain KS, Belani CP, Bonomi P, et al. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 2006;7(6):417-419 (Pubitemid 44043553)
43. Hershberger PA, Vasquez AC, Kanterewicz B, et al. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65(4):1598-1605
44. Richardson TP, Peters MC, Ennett AB, et al. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19(11):1029-1034 (Pubitemid 33041886)
45. Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004;320(1):226-232 (Pubitemid 38781805)
46. Lavi G, Voronov E, Dinarello CA, et al. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 2007;123(2):123-130 (Pubitemid 47562137)
47. Sun X, Qiao H, Jiang H, et al. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005;12(1):35-45 (Pubitemid 39665241)
48. Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65(19):8984-8992 (Pubitemid 41377390)
49. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008;16(5):942-946 (Pubitemid 351587105)
50. Seymour LW, Miyamoto Y, Maeda H, et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995;31A(5):766-770
51. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20(6):1668-1676 (Pubitemid 34260549)
52. Yockman JW, Kim WJ, Chang CW, et al. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Ther 2007;14(19):1399-1405
53. Duncan R, Vicent MJ, Greco F, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer 2005;12(Suppl 1):S189-99 (Pubitemid 41395426)
54. Venne A, Li S, Mandeville R, et al. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996;56(16):3626-3629 (Pubitemid 26272000)
55. Danson S, Ferry D, Alakhov V, et al. PhaseI dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004;90(11):2085-2091 (Pubitemid 38869710)
56. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10(3):255-261 (Pubitemid 38667615)
57. Satchi-Fainaro R, Hailu H, Davies JW, et al. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem 2003;14(4):797-804
58. Danhauser-Riedl S, Hausmann E, Schick HD, et al. PhaseI clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993;11(2-3):187-195
59. Wachters FM, Groen HJ, Maring JG, et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer 2004;90(12):2261-2267 (Pubitemid 38961887)
60. Devalapally H, Shenoy D, Little S, et al. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol 2007;59(4):477-484
61. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6(9):688-701
62. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008;126(3):187-204
63. Cavallaro G, Campisi M, Licciardi M, et al. Reversibly stable thiopolyplexes for intracellular delivery of genes. J Control Release 2006;115(3):322-334 (Pubitemid 44634841)
64. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54(4):987-992 (Pubitemid 24085451)
65. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003;8(Suppl 2):3-9 (Pubitemid 37152051)
66. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14(8):2353-2364 (Pubitemid 26264888)
67. Mackenzie MJ, Hirte HW, Siu LL, et al. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3weeks in patients with solid cancers. Ann Oncol 2004;15(4):665-670
68. White SC, Lorigan P, Margison GP, et al. PhaseII study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95(7):822-828 (Pubitemid 44498096)
69. Li X, Ruan GR, Lu WL, et al. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release 2006;112(2):186-198
70. Straubinger RM, Hong K, Friend DS, et al. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell 1983;32(4):1069-1079
71. Knoll G, Burger KN, Bron R, et al. Fusion of liposomes with the plasma membrane of epithelial cells: fate of incorporated lipids as followed by freeze fracture and autoradiography of plastic sections. J Cell Biol 1988;107(6 Pt 2):2511-2521 (Pubitemid 19019397)
72. Mahmud A, Xiong XB, Lavasanifar A. Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery. Eur J Pharm Biopharm 2008;69(3):923-934
73. Gabizon AA, Tzemach D, Horowitz AT, et al. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 2006;12(6):1913-1920
74. Rijcken CJ, Soga O, Hennink WE, et al. Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery. J Control Release 2007;120(3):131-148 (Pubitemid 47058635)
75. Harata M, Soda Y, Tani K, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 2004;104(5):1442-1449 (Pubitemid 39166523)
76. Lappi DA. Tumor targeting through fibroblast growth factor receptors. Semin Cancer Biol 1995;6(5):279-288
77. Kleeff J, Fukahi K, Lopez ME, et al. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 2002;9(6):522-532 (Pubitemid 34569035)
78. Shmeeda H, Mak L, Tzemach D, et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006;5(4):818-824 (Pubitemid 43724580)
79. Xiong XB, Mahmud A, Uludag H, et al. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res 2008;25(11):2555-2566
80. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993;90(19):8996-9000 (Pubitemid 23306438)
81. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-427 (Pubitemid 38173977)
82. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25(5):540-547 (Pubitemid 350002961)
83. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380(6572):364-366 (Pubitemid 26097120)
84. Pauli BU, Augustin-Voss HG, el-Sabban ME, et al. Organ-preference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev 1990;9(3):175-189
85. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15(6):542-546 (Pubitemid 27251571)
86. Lee TY, Lin CT, Kuo SY, et al. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007;67(22):10958-10965
87. Huang X, Molema G, King S, etal. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275(5299):547-550
88. Ramakrishnan S, Olson TA, Bautch VL, et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation invitro and angiogenesis in vivo. Cancer Res 1996;56(6):1324-1330 (Pubitemid 26084349)
89. Veenendaal LM, Jin H, Ran S, et al. Invitro and invivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 2002;99(12):7866-7871 (Pubitemid 34650971)
90. Vasey PA, Kaye SB, Morrison R, etal. PhaseI clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign PhaseI/II Committee. Clin Cancer Res 1999;5(1):83-94